A client is planning a trip to Haiti and is concerned about becoming infected with malaria. Which medication can the client take prophylactically to prevent becoming infected?

Introduction: Malaria is a protozoal infection caused by Plasmodium species transmitted via the Anopheles mosquito. Chemoprophylaxis involves the administration of antimalarial agents to individuals traveling to endemic regions to prevent the hepatic or erythrocytic stages of the parasite from establishing a systemic infection. A. CHLOROQUINE PHOSPHATE is a classic antimalarial used for PROPHYLAXIS in regions where Plasmodium falciparum remains sensitive to the drug. It works by inhibiting the parasite's ability to detoxify heme. For travelers to Haiti, it is often started 1 to 2 weeks before travel and continued during and after the trip. B. Metronidazole is an antiprotozoal and antibacterial agent primarily used for anaerobic bacterial infections, amebiasis, and trichomoniasis. It does not have clinical efficacy against the Plasmodium species that cause malaria and therefore cannot be used as a prophylactic agent for travelers headed to endemic areas. C. Griseofulvin is an antifungal medication specifically used for dermatophyte infections of the skin, hair, and nails (tinea infections). Its mechanism involves disrupting the mitotic spindle of fungal cells. It has zero activity against protozoal parasites and is irrelevant for the prevention of malaria during international travel. D. Fluconazole is a triazole antifungal agent used to treat systemic or localized candidiasis and cryptococcal meningitis. It inhibits fungal cytochrome P450-dependent enzymes. Like griseofulvin, it has no antiparasitic properties and provides no protection against the transmission or development of malaria in humans.